Skip to main content
Sunday, November 15, 2026Nov 15

US bets on untested company to deliver COVID-19 vaccine

This undated image provided by ApiJect Systems America in July 2020 shows a prototype of their "BFS" prefilled syringe. The devices are self-contained: the soft plastic blister is squeezed to push a dosage through the attached needle to inject into a patient. It also includes a computer chip that can transmit information about the drug, dose, location and time of administration. When precious vats of COVID-19 vaccine are finally ready, the ability to jab the lifesaving solution into the arms of Americans will require hundreds of millions of injections. The Trump administration  has agreed to invest more than half a billion in tax dollars in ApiJect Systems America, a young company whose injector is not approved by federal health authorities and who hasn't yet set up a factory to manufacture the unapproved devices. (ApiJect Systems America via AP)
This undated image provided by ApiJect Systems America in July 2020 shows a prototype of their "BFS" prefilled syringe. The devices are self-contained: the soft plastic blister is squeezed to push a dosage through the attached needle to inject into a patient. It also includes a computer chip that can transmit information about the drug, dose, location and time of administration. When precious vats of COVID-19 vaccine are finally ready, the ability to jab the lifesaving solution into the arms of Americans will require hundreds of millions of injections. The Trump administration has agreed to invest more than half a billion in tax dollars in ApiJect Systems America, a young company whose injector is not approved by federal health authorities and who hasn't yet set up a factory to manufacture the unapproved devices. (ApiJect Systems America via AP)

When precious vats of COVID-19 vaccine are finally ready, jabbing the lifesaving solution into the arms of Americans will require hundreds of millions of injections.

As part of its strategy to administer the vaccine as quickly as possible, the Trump administration has agreed to invest more than half a billion in tax dollars in ApiJect Systems America, a young company. Its injector is not approved by federal health authorities and the company hasn’t yet set up a factory to manufacture the devices.

The commitment to ApiJect dwarfs the other needle orders the government has placed with a major manufacturer and two other small companies.

___

EDITOR’S NOTE — This story is part of an ongoing investigation by The Associated Press, the PBS series FRONTLINE and the Global Reporting Centre that examines the deadly consequences of the fragmented worldwide medical supply chain.